Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node
Status: Enrolling
Updated:  9/18/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node
Status: Enrolling
Updated: 9/18/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node
Status: Enrolling
Updated:  9/18/2015
Peter MacCallum Cancer Centre
mi
from
East Melbourne,
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node
Status: Enrolling
Updated: 9/18/2015
Peter MacCallum Cancer Centre
mi
from
East Melbourne,
Click here to add this to my saved trials
Efficacy Study of an Educational Program for Decision Support for Breast Cancer
Assessing the Efficacy of a CDSS for Breast Cancer
Status: Enrolling
Updated:  9/18/2015
Baylor College of Medicine
mi
from
Houston, TX
Efficacy Study of an Educational Program for Decision Support for Breast Cancer
Assessing the Efficacy of a CDSS for Breast Cancer
Status: Enrolling
Updated: 9/18/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Texas Oncology-Abilene
mi
from
Abilene, TX
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Texas Oncology-Abilene
mi
from
Abilene, TX
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Texas Oncology-Beaumont
mi
from
Beaumont, TX
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Texas Oncology-Beaumont
mi
from
Beaumont, TX
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Us Oncology Central Pharmacy
mi
from
Fort Worth, TX
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Us Oncology Central Pharmacy
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Rosario,
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Rosario,
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Virginia K. Crosson Cancer Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Pacific Shores Medical Group
mi
from
Long Beach, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Pacific Shores Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
North Valley Hematology-Oncology Medical Group
mi
from
Northridge, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
North Valley Hematology-Oncology Medical Group
mi
from
Northridge, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Cancer Care Associates Medical Group, Inc.
mi
from
Redondo Beach, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Cancer Care Associates Medical Group, Inc.
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Sansum- Santa Barbara medical foundation Clinic
mi
from
Santa Barbara, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Sansum- Santa Barbara medical foundation Clinic
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Santa Barbara Hematology Oncology Medical Group, Inc.
mi
from
Santa Barbara, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Santa Barbara Hematology Oncology Medical Group, Inc.
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
San Diego Cancer Center
mi
from
Vista, CA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
San Diego Cancer Center
mi
from
Vista, CA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Suburban Hematology/Oncology Associates, Pc
mi
from
Lawrenceville, GA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Suburban Hematology/Oncology Associates, Pc
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Oncology/Hematology Associates of Central Illinois, P.C.
mi
from
Peoria, IL
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Oncology/Hematology Associates of Central Illinois, P.C.
mi
from
Peoria, IL
Click here to add this to my saved trials
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated:  9/23/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor
Status: Enrolling
Updated: 9/23/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival
Status: Enrolling
Updated:  9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival
Status: Enrolling
Updated: 9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Status: Enrolling
Updated:  9/23/2015
Michigan State University
mi
from
East Lansing, MI
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Status: Enrolling
Updated: 9/23/2015
Michigan State University
mi
from
East Lansing, MI
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Miami, FL
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Chicago, IL
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Zion, IL
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Zion, IL
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Bethesda, MD
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Detroit, MI
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
St. Louis, MO
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Durham, NC
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Seattle, WA
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Bruxelles,
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Washington,
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Indianapolis, IN
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Sioux City, IA
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Sioux City, IA
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Boston, MA
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Minneapolis, MN
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Rochester, MN
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Albuquerque, NM
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Cary, NC
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Cary, NC
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Portland, OR
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Philadelphia, PA
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Pittsburgh, PA
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Spartanburg, SC
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Dallas, TX
Brain Metastases In ErbB2-Positive Breast Cancer
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials